The prevalence of drug resistance has become an important
issue in various yeast infections, which have significant effects on both human
animal health. In this study, an attempt has been made to determine
susceptibility pattern of two antifungal agents Terbinafine and Ketoconazole
against 45 oral and non-oral Candida albicans isolates using broth
microdilution method. Under in vitro conditions, results showed that (42/45)
93% of the C. albicans isolates had MIC values indicating susceptibility to
Ketoconazole (≤0.125 μg/ml) and MICs ranged from ≤0.03125-8.0 μg/ml.
According to Terbinafine, (40/45) 88.9% of isolates had MICs less than 4 μg/ml
and MICs ranged from 0.25-8.0 μg/ml. This is the first report of in vitro
antifungal susceptibility data to be published from Palestine against clinical
isolates of Candida albicans. Availability of sensitive and highly accurate
antifungal susceptibility testing methods, can permit analysis of data in vitro
and with outcome in vivo, important to assist physician for making appropriate
drug choices and patient management decision. These data indicated that
Terbinafine and Ketoconazole are still active against C. albicans and
maytherefore have clinical applications against some of these organisms.
Attachment | Size |
---|---|
Susceptibility_of_Candida_albicans_isolates_to_Terbinafine_and_Ketoconazole.pdf | 100.88 KB |